Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2003
|
| gptkbp:ATCCode |
J05AE08
|
| gptkbp:CASNumber |
198904-31-3
|
| gptkbp:chemicalFormula |
C38H52N6O7
|
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:eliminationHalfLife |
7 hours
|
| gptkbp:form |
capsule
oral powder |
| gptkbp:genericName |
gptkb:atazanavir
|
| https://www.w3.org/2000/01/rdf-schema#label |
Reyataz
|
| gptkbp:indication |
antiretroviral therapy
|
| gptkbp:interactsWith |
gptkb:proton_pump_inhibitors
gptkb:rifampin gptkb:ritonavir gptkb:St._John's_Wort antacids |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:metabolism |
liver
|
| gptkbp:patentExpired |
2017
|
| gptkbp:pregnancyCategory |
B
|
| gptkbp:proteinBinding |
86%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache jaundice hyperbilirubinemia |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:Atazanavir
gptkb:atazanavir |
| gptkbp:bfsLayer |
7
|